Corrigendum to Antiviral effect of high-dose ivermectin in adults with COVID-19: A proof-of-concept randomized trial (2021)

Peer-Reviewed Study · Krolewiecki A, Lifschitz A, Moragas M, Travacio M, Valentini R, Alonso DF, et al. · September 2021

Krolewiecki A et al., 2021-09: Publisher correction to the 2021 high-dose ivermectin trial; the trial itself stands. Recorded so the dose evidence is not cited without its correction notice.

Krolewiecki A et al., 2021-09: Publisher correction to the 2021 high-dose ivermectin trial; the trial itself stands. Recorded so the dose evidence is not cited without its correction notice. C2 status notice. Record field: the PubMed record's only text is '[This corrects the article DOI: 10.1016/j.eclinm.2021.100959.]', so key_excerpt is left empty rather than paraphrased; confidence MEDIUM. Study type: corrigendum (not a retraction or expression of concern) – the 34189446 trial remains published and citable. Document date 2021-09 (EClinicalMedicine vol 39). No funder or conflicts of interest recorded for a correction notice. Study type: other.